Shengli Wan

523 total citations · 1 hit paper
19 papers, 384 citations indexed

About

Shengli Wan is a scholar working on Biomaterials, Molecular Biology and Biomedical Engineering. According to data from OpenAlex, Shengli Wan has authored 19 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Biomaterials, 7 papers in Molecular Biology and 5 papers in Biomedical Engineering. Recurrent topics in Shengli Wan's work include Nanoparticle-Based Drug Delivery (9 papers), Nanoplatforms for cancer theranostics (4 papers) and Extracellular vesicles in disease (3 papers). Shengli Wan is often cited by papers focused on Nanoparticle-Based Drug Delivery (9 papers), Nanoplatforms for cancer theranostics (4 papers) and Extracellular vesicles in disease (3 papers). Shengli Wan collaborates with scholars based in China and Thailand. Shengli Wan's co-authors include Jianming Wu, Qingze Fan, Yuesong Wu, Haiyang Hu, Jingqing Zhang, Xiaoqin Tang, Jia Lai, Jiesi Luo, Xiaogang Zhou and Long Wang and has published in prestigious journals such as ACS Applied Materials & Interfaces, Pharmaceutical Research and Colloids and Surfaces B Biointerfaces.

In The Last Decade

Shengli Wan

19 papers receiving 377 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment

2022 164 citations Yuesong Wu, Shengli Wan et al. Journal of Nanobiotechnology profile →

Peers

Shengli Wan

BIOMA

IMMUN

Tijia Chen China

Yuesong Wu China

Xianyan Qin China

Shuwen Cao China

Yanpeng Liu China

Qingqing Xiao China

Lingran Du China

Shuyi Xiao China

Martina Di Francesco Italy

Maggie Lu United States

Tijia Chen China

Shengli Wan

131 ×1.0

124 ×1.0

142 ×1.2

BIOMA

44 ×0.8

IMMUN

28 ×0.7

Citations per year, relative to Shengli Wan Shengli Wan (= 1×) peers Tijia Chen

Countries citing papers authored by Shengli Wan

Since Specialization

Citations

This map shows the geographic impact of Shengli Wan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengli Wan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengli Wan more than expected).

Fields of papers citing papers by Shengli Wan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengli Wan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengli Wan. The network helps show where Shengli Wan may publish in the future.

Co-authorship network of co-authors of Shengli Wan

This figure shows the co-authorship network connecting the top 25 collaborators of Shengli Wan. A scholar is included among the top collaborators of Shengli Wan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengli Wan. Shengli Wan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Liu, Yang, Xingyue Wang, Shu‐Rong Wang, et al.. (2025). Targeting lipid metabolism in regulatory T cells for enhancing cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1880(2). 189259–189259. 9 indexed citations

Yang, Peng, et al.. (2025). Nanozyme-Based Therapy in Gout. ACS Applied Materials & Interfaces. 17(28). 39863–39879. 1 indexed citations

Wu, Yuesong, Qingze Fan, Haiyang Hu, et al.. (2024). Biomimetic platelet-like nanoparticles enhance targeted hepatocellular carcinoma therapy. Colloids and Surfaces B Biointerfaces. 240. 113973–113973. 5 indexed citations

Wan, Shengli, et al.. (2024). Cancer cell membrane-camouflaged paclitaxel/PLGA nanoparticles for targeted therapy against lung cancer. Biomedicine & Pharmacotherapy. 177. 117102–117102. 10 indexed citations

Liu, Yuanzhi, Linwei Zhang, Long Wang, et al.. (2024). Targeting CD38/ ADP-ribosyl cyclase as a novel therapeutic strategy for identification of three potent agonists for leukopenia treatment. Pharmacological Research. 200. 107068–107068. 3 indexed citations

Li, Yaping, et al.. (2024). Causal relationship between dietary intake and IgA nephropathy: a Mendelian randomization study. Frontiers in Nutrition. 11. 1400907–1400907. 1 indexed citations

Liu, Honghua, et al.. (2023). Application of a novel coagulant in reservoir water treatment in Qingdao. Desalination and Water Treatment. 284. 49–60. 32 indexed citations

Wan, Shengli, Qingze Fan, Yuesong Wu, et al.. (2023). Curcumin-Loaded Platelet Membrane Bioinspired Chitosan-Modified Liposome for Effective Cancer Therapy. Pharmaceutics. 15(2). 631–631. 25 indexed citations

Wu, Yuesong, Shengli Wan, Shuo Yang, et al.. (2022). Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment. Journal of Nanobiotechnology. 20(1). 542–542. 164 indexed citations breakdown →

10.

Liu, Yuanzhi, Yilan Huang, Jingyan Li, et al.. (2022). A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis. Frontiers in Pharmacology. 13. 1010626–1010626. 5 indexed citations

11.

Liu, Yang, Shiwei Guo, Haiyang Hu, et al.. (2022). Preparation and optimization of poly (lactic-co-glycolic acid) rod-shaped particles in nano size range for paclitaxel delivery. Frontiers in Bioengineering and Biotechnology. 10. 1103990–1103990. 2 indexed citations

12.

Wu, Yan, Shengli Wan, Yun Chen, et al.. (2022). Biomimetic lipidic nanovectors for effective asparaginase supramolecule delivery. Nanomedicine Nanotechnology Biology and Medicine. 41. 102518–102518. 3 indexed citations

13.

Chen, Qi, Fahsai Kantawong, Shengli Wan, et al.. (2022). Identification of a Mitochondria-Related Gene Signature to Predict the Prognosis in AML. Frontiers in Oncology. 12. 823831–823831. 15 indexed citations

14.

Hu, Haiyang, Shengli Wan, Yuesong Wu, et al.. (2022). Fabrication, Optimization, and Evaluation of Paclitaxel and Curcumin Coloaded PLGA Nanoparticles for Improved Antitumor Activity. ACS Omega. 8(1). 976–986. 25 indexed citations

15.

Wan, Shengli, Yuesong Wu, Qingze Fan, et al.. (2022). Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting. Pharmaceutics. 14(12). 2614–2614. 5 indexed citations

16.

Wan, Shengli, et al.. (2016). Chitosan-modified lipid nanovesicles for efficient systemic delivery of l-asparaginase. Colloids and Surfaces B Biointerfaces. 143. 278–284. 30 indexed citations

17.

Zhou, Qixin, Dan He, Shengli Wan, et al.. (2015). Nanosomal Microassemblies for Highly Efficient and Safe Delivery of Therapeutic Enzymes. ACS Applied Materials & Interfaces. 7(36). 20255–20263. 24 indexed citations

18.

Wan, Shengli, Meng Zhong, Mei Yang, Xueyuan Hu, & Jingqing Zhang. (2015). [Pharmacokinetics and Intestinal Absorption of Curcumin Chitosan Hydrochloride Coated Liposome in Rats].. PubMed. 38(1). 132–5. 1 indexed citations

19.

Meng, Zhongwei, Yue Feng, Hong Liao, et al.. (2014). Azithromycin Cationic Non-Lecithoid Nano/Microparticles Improve Bioavailability and Targeting Efficiency. Pharmaceutical Research. 31(10). 2857–2867. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact